Multiple Sclerosis and Magnetic Resonance Imaging: Present Status and New Trends

Česká verzia

Authors: M. Vaněčková ¹; Z. Seidl ^1,2
Authors place of work: Radiodiagnostická klinika, oddělení MR, 1. LF UK a VFN v Praze ¹; Vysoká škola zdravotnická, Praha ²
Published in the journal: Cesk Slov Neurol N 2008; 71/104(6): 664-672
Category: Review Article

Práce vznikla za podpory výzkumného záměru MZOVFN2005 a MSMOO21620849.

Summary

The article focuses on the role of magnetic resonance imaging (MRI) in the diagnosis of multiple sclerosis (MS). MRI plays a major role in the diagnosis of MS; it is the most important paraclinical test and is irreplaceable in detecting the activity of the disease. Standard techniques used for MS monitoring are presented in the article, such as lesion load and brain atrophy, together with the new criteria. Briefly discussed are unconventional MRI techniques, such as magnetization transfer, diffusion-weighted imaging, perfusion-weighted imaging, functional MR imaging, relaxometry and magnetic resonance spectroscopy.

Key words:
multiple sclerosis – magnetic resonance imaging – diagnostic criteria – atrophy – magnetization transfer – diffusion-weighted imaging – perfusion-weighted imaging – functional MR imaging – relaxometry – magnetic resonance spectroscopy

Zdroje

1. Fazekas F, Offenbacher H, Fuchs S, Schmidt R, Niederkorn K, Horner S et al. Criteria for an increased specificity of MR interpretation in elderly subjects with suspected multiple sclerosis. Neurology 1988; 38(12): 1822–1825.

2. Paty DW, Oger JF, Kastrukoff LF, Hashimoto SA, Hooge JP, Eisen AA et al. MR in the diagnosis of MS: a prospective study with comparison of clinical evaluation, evoked potentials, oligoclonal banding, and CT. Neurology 1988; 38(2): 180–185.

3. Barkhof F, Filippi M, Miller DH, P Scheltens, A Campi, CH Polman et al. Comparison of MR imaging criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain 1997; 120(11): 2059–2069.

4. Tintoré M, Rovira A, Martinez MJ, Rio J,Díaz-Villoslada P, Brieva L et al. Isolated demyelinating syndromes: comparison of different MR imaging criteria to predict conversion to clinically definite multiple sclerosis. AJNR Am J Neuroradiol 2000; 21(4): 702–706.

5. Stewart WA, Hall LD, Berry K, Paty DW. Correlation between NMR scan and brain slice data in multiple sclerosis. Lancet 1984; 2(8399): 412.

6. Miller DH, Barkhof F, Nauta JJ. Gadolinium enhancement increases the sensitivity of MR in detecting disease activity in multiple sclerosis. Brain 1993; 116(5): 1077–1094.

7. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mörk S, Bö L. Axonal transection in the multiple sclerosis. Engl J Med 1998; 338(5): 278–285.

8. Lassmann H. Mechanisms of demyelination and tissue destruction in multiple sclerosis. Clin Neurol Neurosurg 2002; 104(3): 168–171.

9. Barkhof F. MR in multiple sclerosis: correlation with Expanded Disability Status Scale (EDSS). Mult Scler 1999; 5(4): 283–286.

10. Lucchinetti C, Brück W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 2000; 47(6): 707–717.

11. Baratti C, Yousry T, Kadziora C, Spuler S,Mammi S. Comparison of fast-FLAIR vs Standard SE sequences for measurement of brain MR lesion loads in patients with multiple sclerosis. Neuroradiology 1995; 37: 90–95.

12. Seidl Z, Obenberger J. Magnetická rezonance jako modalita diagnostiky roztroušené sklerózy mozkomíšní. Současná realita, literární přehled doplněný zkušeností našeho pracoviště a budoucí perspektivy využití MR. Cesk Slov Neurol N 1998; 61/94(3): 118–128.

13. Ciccarelli O, Brex PA, Thompson AJ, Miller DH. Disability and lesion load in MS: a reassessment with MS functional composite score and 3D fast FLAIR. J Neurol 2002; 249(1): 18–24.

14. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 50(1): 121–127.

15. Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the „McDonald Criteria“. Ann Neurol 2005; 58(6): 840–846.

16. Swanton JK, Rovira A, Tintore M, Altmann DR, Barkhof F, Filippi M et al. MR criteria for multiple sclerosis in patients presenting with clinically isolated syndromes: a multicentre retrospective study. Lancet Neurol 2007; 6(8): 677–686.

17. Swanton JK, Fernando K, Dalton CM, Miszkiel KA, Thompson AJ, Plant GT et al. Modification of MR criteria for multiple sclerosis in patients with clinically isolated syndromes. J Neurol Neurosurg Psychiatry 2006; 77(7): 830–833.

18. Silver NC, Good CD, Barker GJ, MacManus DG, Thompson AJ, Moseley IF et al. Sensitivity of contrast enhanced MR in multiple sclerosis. Effects of gadolinium dose, magnetisation transfer contrast and delayed imaging. Brain 1997; 120(7): 1749–1761.

19. Filippi M, Capra R, Campi A, Colombo B,Prandini F, Marcianò N et al. Triple dose of gadolinium-DTPA and delayed MR in patients with bening multiple sclerosis. J Neurol Neurosurg Psychiatry 1996; 60(5): 526–530.

20. Molyneux PD, Filippi M, Barkhof F, Gasperini C, Yousry TA, Truyen L et al. Correlations between monthly enhanced MR lesion rate and changes in T2 lesion volume in multiple sclerosis. Ann Neurol 1998; 43(3): 332–339.

21. Kidd D, Thorpe JW, Kendall BE, Barker GJ, Miller DH, McDonald WI et al. MR dynamics of brain and spinal cord in progressive multiple sclerosis. J Neurol Neurosurg Psychiatry 1996; 60(1): 15–19.

22. Losseff N, Kingsley D, McDonald WI Miller DH, Thompson AJ. Clinical and magnetic resonance imaging predictors in primary and secondary progressive multiple sclerosis. Mult Scler 1996; 1(4): 218–222.

23. Miller DH, Grossman RI, Reingold SC, McFarland HF. The role of magnetic resonance techniques in understanding and managing multiple sclerosis. Brain 1998; 121(1): 3–24.

24. Vaněčková M, Seidl Z, Krásenský J, Obenberger J, Havrdová E, Viták T et al. Sledování objemu ložisek u roztroušené sklerózy mozkomíšní magnetickou rezonancí. Cesk Slov Neurol N 2002; 65/98(3): 175–179.

25. Brex PA, Ciccarelli O, O‘Riordan JI, Sailer M, Thompson AJ, Miller DH. A longitudinal study of abnormalities on MR and disability from multiple sclerosis. N Engl J Med 2002; 346(3): 158–164.

26. Sailer M, Losseff NA, Wang L, Gawne-Cain ML, Thompson AJ, Miller DH. T1 lesion load and cerebral atrophy as a marker for clinical progression in patients with multiple sclerosis. A prospective 18 months follow‑up study. Eur J Neurol 2001; 8(1): 31–42.

27. Rudick RA, Fisher E, Lee JC, Simon J, Jacobs L. Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS. Multiple Sclerosis Collaborative Research Group. Neurology 1999; 53(8): 1698–1704.

28. Filippi M, Rovaris M, Iannucci G, Mennea S, Sormani P, Comi G. Whole brain volume changes in patients with progressive MS treated with cladribine. Neurology 2000; 55(11): 1714–1718.

29. Yulin GE, Grossman RI, Udupa JK, Babb JS, Nyúl LG, Kolson LD. Brain atrophy in Relapsing-Remitting Multiple Sclerosis: Fractional Volumetric Analysis of Gray Matter and White Matter. Neuroradiology 2001; 220(3): 606–610.

30. Fisher E, Rudick RA, Cutter G, Baier M, Miller D, Weinstock-Guttman B et al. Relationship between brain atrophy and disability: an 8-year follow‑up study of multiple sclerosis patients. Mult Scler 2000; 6(6): 373–377.

31. Havrdova E, Horakova D, Pospisilova L, Cox J, Dwyer M, Seidl Z et al. ApoE epsilon 4 positivity does not predict more severe clinical and MR outcome: A 5-year longitudinal study. Neurology 2007; 12 (Suppl 1):A164–A164.

32. Schreiber K, Sørensen PS, Koch-Henriksen N, Wagner A, Blinkenberg M, Svarer C et al. Correlations of brain MR parameters to disability in multiple sclerosis. Acta Neurol Scand 2001; 104(1): 24–30.

33. Zivadinov R, Rudick RA, De Masi R, Nasuelli D, Ukmar M, Pozzi-Mucelli RS et al. Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS. Neurology 2001; 57(7): 1239–1247.

34. Horakova D, Cox JL, Havrdova E, Hussein S, Dolezal O, Cookfair D et al. Evolution of different MR measures in patients with active relapsing-remitting multiple sclerosis over 2 and 5 years: a case control study. J Neurol Neurosurg Psychiatry 2008; 79(4): 407–414.

35. Bielekova B, Kadom N, Fisher E, Jeffries N, Ohayon J, Richert N et al. MR as a marker for disease heterogeneity in multiple sclerosis. Neurology 2005; 65(7): 1071–1076.

36. Vaneckova M, Seidl Z, Krasensky J, Havrdova E, Horakova D, Dolezal O et al. The predictive ability of magnetic resonance imaging to progression of clinical disability in patients with multiple sclerosis. J Neurol 2007; 254 (Suppl 3): III/163.

37. Miller DH, Thompson AJ, Filippi M.Magnetic resonance studies of abnormalities in the normal appearing white matter and grey matter in multiple sclerosis. J Neurol 2003; 250(12): 1407–1419.

38. Vrenken H, Rombouts SA, Pouwels PJ, Barkhof F. Voxel‑based analysis of quantitative T1 maps demonstrates that multiple sclerosis acts troughout the normal-appearing white matter. AJNR Am J Neuroradiol 2006; 27(4): 868–874.

39. Wolff SD, Balaban RS. Magnetization transfer imaging: practical aspects and clinical applications. Radiology 1994; 192(3): 593–599.

40. Iannucci G, Rovaris M, Giacomotti L,Comi G, Filippi M. Correlation of multiple sclerosis measures ferived from T2-weighted, T1-weighted, magnetization transfer and diffusion tensor MR imaging. AJNR Am J Neuroradiol 2001; 22(8): 1462–1467.

41. Seidl Z, Obenberger J, Daneš J, Viták T,Krásenský J, Belšán T. Využití magnetizačního transferu při zobrazování magnetickou rezonancí v CNS. Čes Radiol 1997; 51(4): 223–226.

42. Filippi M, Grossman RI. MR techniques to monitor MS evolution: The present and the future. Neurology 2002; 58: 1147–1153.

43. Hiehle JF jr, Grossman RI, Ramer KN, Gonzalez-Scarano F, Cohen JA. Magnetization transfer effects in MR–detected multiple sclerosis lesions:comparison with gadolinium-enhanced spin‑echo images and nonenhanced T1-weighted images. AJNR Am J Neuroradiol. 1995; 16(1): 69–77

44. Ge Y, Grossman RI, Udupa JK, Babb JS, Mannon LJ, McGowan J. Magnetization transfer ratio histogram analysis of normal-appearing gray matter and normal-appearing white matter in multiple sclerosis. J Comput Assist Tomogr 2002; 26(1): 62–68.

45. Ranjeva JP, Audoin B, Au Duong MV, Ibarrola D, Confort-Gouny S, Malikova I et al. Local tissue damage assessed with statistical mapping analysis of brain magnetization transfer ratio: relationship with functional status of patients in the earliest stage of multiple sclerosis AJNR Am J Neuroradiol 2005; 26(1): 119–127.

46. Schmierer K, Scaravilli F, Altman D, Barker GJ, Miller DH. Magnetization transfer ratio and myelin in postmortem multiple sclerosis brain. Ann Neurol 2004; 56(3): 407–415.

47. Filippi M, Agosta F. Magnetization transfer MR in multiple sclerosis. J Neuroimaging 2007; 17 (Suppl 1): 22S–26S.

48. Seidl Z, Vaněčková M. Magnetická rezonance hlavy, mozku a páteře. Praha: Grada Publishing 2007.

49. Rovaris M, Filippi M. Diffusion tensor MR in multiple sclerosis. J Neuroimaging 2007; 17 (Suppl 1): 27S–30S.

50. Rovaris M, Gallo A, Valsasina P, Benedetti B, Caputo D, Ghezzi A et al. Short‑term accrual of gray matter pathology in patients with progressive multiple sclerosis: an in vivo study using diffusion tensor MR. Neuroimage 2005; 24(4): 1139–1146.

51. Filippi M, Cercignani M, Inglese M, Horsfield MA, Comi G. Diffusion tensor magnetic resonance imaging in multiple sclerosis. Neurology 2001; 56(3): 304–311.

52. Arnold DL, Riess GT, Mathews PM, Francis GS, Collins DL, Wolfson C et al. Use of the proton magnetic resonance spectroscopy for monitoring disease progression in multiple sclerosis. Ann Neurol 1994; 36(1): 76–82.

53. De Stefano N, Filippi M. MR spectroscopy in multiple slerosis. J Neuroimaging 2007; 17 (Suppl 1): 31S–35S.

54. Wuerfel J, Bellman-Strobl J, Brunecker P, Aktas O, McFarland H, Villringer A et al. Changes in cerebral perfusion precede plaque formation in multiple sclerosis: a longitudinal perfusion MR study. Brain 2004; 127 (1): 111–119.

55. Inglese M, Adhya S, Johnson G, Babb JS, Miles L, Jaggi H et al. Perfusion magnetic resonance imaging correlates of neuropsychological impairment in multiple sclerosis. J Cereb Blood Flow Metab 2008; 28(1): 164–171.

56. Vymazal J, Righini A, Brooks RA, Canesi M, Mariani C, Leonardi M et al. T1 and T2 in the brain of healthy subjects, patients with Parkinson disease, and patients with multiple system atrophy: relation to iron content. Radiology 1999; 211(2): 489–495.

57. Stankiewicz J, Panter SS, Neema M, Arora A, Batt C, Bakshi R. Iron in chronic brain disorders: imaging and neurotherapeutic implications. Neurotherapeutics 2007; 4(3): 371–386.

58. Neema M, Stankiewicz J, Arora A, Dandamudi V, Batt C, Guss ZD et al. T1- and T2‑based MR measures of diffuse gray matter and white matter damage in patients with multiple sclerosis. J Neuroimaging 2007; 17 (Suppl 1): 16S–21S.

59. Ge Y, Jensen JH, Lu H, Helpern JA, Miles L, Inglese M et al. Quantitative assessment of iron accumulation in the deep gray matter of multiple sclerosis by magnetic field correlation imaging. AJNR Am J Neuroradiol 2007; 28(9): 1639–1644.

60. Grossman RI, McGowan JC. Perspectives on Multiple Sclerosis. AJNR Am J Neuroradiol 1998; 19(7): 1251–1265.

61. Filippi M, Bakshi R, Rovaris M, Comi G. MR and multiple sclerosis: What happened in the last 10 years. J Neuroimaging 2007; 17 (Suppl 1): 1S–2S.